Martin Haluzík

2 months ago | dom-pubs.onlinelibrary.wiley.com | Martin Haluzík |Katarzyna Cypryk |Agustina Alvarez |Felipe Lauand

1 INTRODUCTION Due to the progressive loss of β-cell function in type 2 diabetes (T2D), advancement to injectable therapy may be required to control hyperglycaemia.1 The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) state that the fixed-ratio combination therapy (FRC) of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin has potent glucose-lowering action and recommends FRCs when treatment targets are not met with either...

May 17, 2023 | pubmed.ncbi.nlm.nih.gov | Libor Vítek |Martin Haluzík

Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software